|
Cadmium & its adverse effects on human
health.
|
|
|
|
|
| Article Type: | Clinical report |
| Subject: |
Cadmium
(Health aspects) Toxicology (Research) |
| Author: | Bernard, A. |
| Pub Date: | 10/01/2008 |
| Publication: | Name: Indian Journal of Medical Research Publisher: Indian Council of Medical Research Audience: Academic Format: Magazine/Journal Subject: Biological sciences; Health Copyright: COPYRIGHT 2008 Indian Council of Medical Research ISSN: 0971-5916 |
| Issue: | Date: Oct, 2008 Source Volume: 128 Source Issue: 4 |
| Topic: | Event Code: 310 Science & research |
| Product: | Product Code: 3339640 Cadmium NAICS Code: 331419 Primary Smelting and Refining of Nonferrous Metal (except Copper and Aluminum) SIC Code: 3339 Primary nonferrous metals, not elsewhere classified |
| Geographic: | Geographic Scope: India Geographic Code: 9INDI India |
|
|
|
| Accession Number: | 192258147 |
| Full Text: |
Cadmium (Cd), a by-product of zinc production, is one of the most
toxic elements to which man can be exposed at work or in the
environment. Once absorbed, Cd is efficiently retained in the human
body, in which it accumulates throughout life. Cd is primarily toxic to
the kidney, especially to the proximal tubular cells, the main site of
accumulation. Cd can also cause bone demineralization, either through
direct bone damage or indirectly as a result of renal dysfunction. In
the industry, excessive exposures to airborne Cd may impair lung
function and increase the risk of lung cancer. All these effects have
been described in populations with relatively high exposures to Cd in
the industrial or in heavily polluted environments. Recent studies,
however, suggest that the chronic low environmental exposure to Cd now
prevailing in industrialized countries can adversely affect the kidneys
and bones of the general population. These studies show consistent
associations between various renal and bone biomarkers and the urinary
excretion of Cd used to assess Cd body burden. The public health impact
of these findings are still unknown. Further research is needed to
ascertain that these associations are truly causal and not secondary to
parallel changes in Cd metabolism and in the bone or kidney function
occurring because of ageing or diseases unrelated to Cd exposure. Key words Biomarkers--cadmium--retinol-binding protein--tubular proteinuria Introduction Cadmium is typically a metal of the 20th century, even though large amounts of this by-product of zinc production have been emitted by non-ferrous smelters during the 19th century. Currently, Cd is mainly used in rechargeable batteries and for the production of special alloys. Although emissions in the environment have markedly declined in most industrialized countries, Cd remains a source of concern for industrial workers and for populations living in polluted areas, especially in less developed countries (1). In the industry, Cd is hazardous both by inhalation and ingestion and can cause acute and chronic intoxications. Cd dispersed in the environment can persist in soils and sediments for decades. When taken up by plants, Cd concentrates along the food chain and ultimately accumulates in the body of people eating contaminated foods. Cd is also present in tobacco smoke, further contributing to human exposure. By far, the most salient toxicological property of Cd is its exceptionally long half-life in the human body. Once absorbed, Cd irreversibly accumulates in the human body, in particularly in kidneys and other vital organs such the lungs or the liver. In addition to its extraordinary cumulative properties, Cd is also a highly toxic metal that can disrupt a number of biological systems, usually at doses that are much lower than most toxic metals (2-4). While the acute toxicity of Cd was discovered as early as in 19th century (5), the possibility that this metal could cause chronic effects in humans was recognized much later with the first reports of pulmonary, bone and renal lesions in industrial workers published in the late 1930s-1940s (6-8). It was the outbreak of the Itai-Itai bone disease in Japan in the 1960s (9) that really drew the attention of the public and regulatory bodies to this heavy metal that had been discharged in the environment at an uncontrolled rate for more than one century. After these early reports of severe intoxication, a number of epidemiological and experimental studies were carried out worldwide in order to characterize the toxicity of Cd and to assess the exposure levels from which this widespread pollutant could threaten human health. These studies have demonstrated that Cd absorbed by inhalation or ingestion can cause irreversible damage to several vital organs, among which the most sensitive are the kidney, the bone and the respiratory tract (10). Adverse effects on these organs were described in subjects with relatively high industrial or environmental exposures as compared to the small amounts of Cd absorbed by the general population. However, from the 1990s, several epidemiological studies conducted mainly in Europe. have reported observations suggesting that Cd can adversely affect the kidneys and bones of the general population of industrialized countries from much lower exposure levels than was believed (2,11,12) The aim of the present article is to summarize current knowledge regarding the risks this widespread pollutant may pose to human health. The review will be focused on the kidney, the critical organ for which dose-response relationships are the best documented. The kidney is also the target organ that can be monitored using well-validated exposure and effect biomarkers. The review will also address some of the issues that complicate the risk assessment of Cd and in particular the inconsistencies between the critical exposure levels derived in industrial workers and in the general population with much lower exposures to environmental Cd. Exposure and metabolism Primary exposure sources of Cd for the general population include food and tobacco smoking. The highest concentrations of Cd (10-100 ppm) are found in internal organs of mammals, mainly in the kidneys and liver (offals) as well as in some species of fish, mussels and oysters, especially when caught in polluted seas. Consumption of staple foods such as wheat, rice also significantly contributes to human exposure. In the industry, Cd exposure is mainly by inhalation although significant amounts of Cd can be ingested via contaminated hands or cigarettes. The amounts of Cd ingested daily with food in most countries are in the range of 10 to 20 [micro]g per day. Tobacco smoking is an important additional source of exposure for smokers. Since one cigarette contains approximately ! to 2 [micro]g Cd, smoking one pack per day results in a daily uptake of Cd that approximates that derived from food. Absorption by the oral route varies around 5 per cent but can be increased up to 15 per cent in subjects with low iron stores. When exposure is by inhalation, it is estimated that between 10 and 50 per cent of Cd is absorbed, depending on the particle size and the solubility of Cd compounds. In the case of Cd in tobacco smoke (mainly in the form of CdO), an average of 10 per cent of Cd is absorbed. Absorption of Cd through the skin is negligible (2,10). Regardless the route of exposure, Cd is efficiently retained in the organism and remains accumulated throughout life. The Cd body burden, negligible at birth, increases continuously during life until approximately the age of about 60-70 yr from which Cd body burden levels off and can even decrease. Cd concentrates in the liver and even more in the kidneys, which can contain up to 50 per cent of the total body burden of Cd in subjects with low environmental exposure. Accumulation of Cd in liver and kidney is due to the ability of these tissues to synthesize metallothionein, a Cd-inducible protein that protects the cell by tightly binding the toxic [Cd.sup.2+] ion. The stimulation of metallothionein by zinc probably explains the protective effect of this essential element towards Cd toxicity. Because of its small size, metallothionein is rapidly cleared from plasma by glomerular filtration before being taken up by the proximal tubular cells. This glomerular-filtration pathway is at the origin of the selective accumulation of Cd in proximal tubular cells and thus in the renal cortex where this segment of the nephron is located (Fig.). Cd does not cross easily the placental or the haemato-encephalic barriers, explaining its very low toxicity to the foetus and the central nervous system as compared with other heavy metals. Cd is mainly eliminated via the urine. The amount of Cd excreted daily in urine is however very low, representing somewhat 0.005 to 0.01 per cent of the total body burden. This low fractional excretion corresponds to a biological half-life of more than 20 yr. Of note, the elimination half-life of Cd is reduced to less than 10 years in subjects with tubular dysfunction (2, 10) [FIGURE OMITTED] There is now a consensus among scientists to say that in chronic Cd poisoning the kidney, which is the main storage organ of Cd, is also the critical target organ, i.e. the first organ to display signs of toxicity (2,3,10,11). Cd nephropathy has been described in industrial workers exposed mainly by inhalation and in the general population exposed via contaminated foods. The various studies conducted on human populations and experimental animals have demonstrated that Cd exerts its renal toxicity in a strictly dose-dependent manner, the adverse effects occurring only when the Cd concentration in kidney cortex reaches a critical threshold. The total concentration of Cd in renal cortex from which renal effects are likely to occur has been estimated at 150-200 ppm ([micro]g/g wet weight of renal cortex), both in human subjects and in experimental animals (2,10,11). As most renal Cd is bound to metallothionein, the form of Cd responsible for renal damage is the highly toxic [Cd.sup.2+] ion that avidly reacts with cellular components. The critical concentration of free Cd in renal cortex corresponding to the critical concentration of 200 ppm for total Cd has been estimated at about 2 ppm (13). The earliest manifestation of Cd-induced renal damage considered as critical consists in an increased urinary excretion of microproteins (molecular weight <40 kD). Among these proteins, [[beta].sub.2]-microglobulin, retinol-binding protein and [alpha.sub.1]-microglobulin have been the most validated for the routine screening of tubular proteinuria. The increased loss of these proteins in urine is a reflection of the decreased tubular reabsorption capacity. In health, these proteins are almost completely reabsorbed by the proximal tubular cells, meaning that a minute decrease of their fractional reabsorption drastically increases their urinary excretion. A modest increase in the urinary excretion of these proteins, as found at the early stage of Cd nephropathy (in the range of 300 to 1,000 [micro]g/g creatinine for retinol-binding protein (Table I), is unlikely to compromise the renal function (4). Such a small increase might even be reversible after removal from Cd exposure. By contrast, when the urinary excretion of these proteins is increased by more than one order of magnitude, tubular dysfunction caused by Cd becomes irreversible and may be associated with a lower glomerular filtration rate (GFR) and an accelerated decline of the GFR with ageing (4) (Table I). Other solutes excreted in greater amounts in the urine of subjects with Cd nephropathy include total protein, albumin, amino acids, enzymes (e.g. N-acetyl-[beta]-D glucosaminidase), tubular antigens, glucose, calcium and phosphate. The disturbances of calcium and phosphate metabolism accompanying Cd nephropathy may lead to bone demineralization, the formation of kidney stones and bone fractures. Prospective studies among inhabitants living in Cd-polluted areas in Japan have shown that the development of Cd-induced proteinuria is predictive of an increased mortality by heart failure, cerebral infarction, nephritis and nephrosis (14). There is some epidemiological evidence that diabetics are more susceptible to the nephrotoxic action of Cd, a finding consistent with animal studies (1,15). Although cases of over Cd nephropathy have been described in the context of high occupational or environmental exposures, recent studies suggest that Cd at the low environmental exposures currently found in industrialized countries can cause subtle renal effects, leading to modest increases in the urinary excretion of microproteins or in small variations of the GFR (15-18). The heath significance of these findings is however difficult to assess. Assuming that these renal effects found in population-based studies are causally related to Cd, these could be potentially adverse, rendering for instance the kidneys more sensitive to other stressors. These effects might also reflect an early renal response to Cd, which could be purely adaptative and/or reversible in nature. Another possibility that should be also considered is that these effects, especially those at very low exposure levels and observed on the same matrix (urine), might be linked through non causal associations. For instance, the associations emerging between proteins and Cd in urine might be the reflection of the dependence of each other on the filtration or reabsorption capacity of the kidneys, which indeed widely varies across the general population, especially among the elderly (19). Bone effects Although first reported in French workers by Nicaud et al (7), toxic effects of Cd on the bones really became evident with the outbreak of the Itai-Itai disease in the Cd-polluted area of Toyama, Japan, after World War II. Itai-Itai disease patients presented, indeed, a severe osteomalacia accompanied with multiple bone fractures and renal dysfunction (9). They complained of pain in the back and in the extremities, difficulties in walking and pain on bone pressure (hence the name Itai-Itai meaning Ouch-Ouch in Japanese). Recent studies in China have confirmed the bone toxicity of Cd. Nordberg et al (20) have found decreased bone mineral density in Chinese farmers exposed to Cd from contaminated rice for more than 20 yr. The bone mass density was decreased in postmenopausal women with elevated Cd in urine or blood as well as among men with elevated Cd in blood. Bone lesions have been regarded for long as late manifestations of intoxication, occurring only after relatively high exposures in the industry or environment. Effects on the bone, especially at high exposure, are largely the consequence of Cd nephropathy, resulting in an altered vitamin D metabolism and a urinary waste of calcium and phosphate. According to studies on environmentally-exposed populations in Japan or China, the thresholds of urinary or blood Cd associated with bone effects are higher than those associated with renal dysfunction (21). This view, however, has been challenged by some recent studies reporting associations between urinary Cd and indices of bone mass density in the general population with very low environmental exposure (22-24). An increased risk of bone fractures with increasing Cd levels in urine has been reported (22). Other authors, however, have failed to evidence an association between urinary Cd and bone mass density or biomarkers of bone toxicity (25). Before translating these findings in terms of public health impact, an important issue to clarify is the direction of causality of these associations. The possibility cannot be excluded, indeed, that the metabolism of Cd and hence the levels of the metal in biological fluids can be altered by disturbances in calcium homeostasis due to menopause, ageing or renal diseases unrelated to Cd (19). Cancer Various regulatory bodies have concluded that there is sufficient evidence to classify Cd as a human carcinogen. The most convincing evidence comes from the finding of increased risks of lung cancer in workers exposed to Cd by inhalation as well as from animal data showing that Cd administered by various routes can produce cancer at multiple sites, including in the lung (26). Although the evidence from animal studies is undisputable, data from occupationally exposed populations require a more careful analysis because of the possible confounding by concomitant exposure to arsenic. Recent studies having adjusted for the concomitant exposure to arsenic and nickel have reported lower relative risks of lung cancer than in the past (2). Cd exposure in the industry has also been linked to prostate and renal cancer but this linkage is much weaker than that for lung cancer. Until recently, studies on populations environmentally exposed to Cd had revealed no increase in cancer mortality, even in populations with Cd-induced renal effects. The possibility that Cd can be involved in environmental carcinogenesis cannot be excluded. In a Cd-polluted region in China, an association between urinary Cd and raised serum concentration of prostate-specific antigen has been found suggesting a possible implication of Cd in prostate carcinogenesis (27). Recently, in a prospective population-based study in Belgium, Nawrot et al (28) have found an association between increased Cd body burden as assessed based on urinary Cd and the development of lung cancer. However, the possibility of a confounding effect by arsenic cannot be excluded in this study (2). The mechanism of Cd carcinogenesis remains largely unknown. Since the metal is not strongly genotoxic and does not cause direct genetic damage, epigenetic mechanisms and/or indirect genotoxic mechanisms such as a blockage of apoptosis, alterations in cell signaling or inhibition of DNA repair might be involved (26). Other effects Impairment of the pulmonary function suggestive of mild obstructive syndrome has been reported in workers exposed to relatively high concentrations of Cd by inhalation. Changes in lung function were however slight as compared to that caused by tobacco smoking (10). With improvement of working conditions in most Cd plants, pulmonary changes are much less likely to occur than biological signs of renal damage. Although Cd can cause liver injury in animals receiving high doses, no study has reported signs of hepatic damage either in Cd workers or among inhabitants of polluted areas. Similarly, there is no report of adverse effects on the nervous system or the reproductive system caused by occupational or environmental exposure to [Cd.sup.2]. Although epidemiologic studies assessing the effects of Cd exposure on blood pressure have provided largely inconsistent results, a recent study in US adults who participated in the 1999-2004 National Health and Nutrition Examination Survey (NHANES) found that Cd levels in blood, but not in urine, were associated with a modest elevation in blood pressure levels (29). Dose-effect/response relationships Cd is one of the environmental pollutants for which dose-response relationships are best documented. The reason for this is that the amount of Cd stored in the critical target organ i.e. the kidney, can be evaluated non invasively using as surrogate indicator the concentration of the metal in urine. Most studies have assessed dose-response relationships for Cd nephrotoxicity by using as exposure indicator, urinary Cd and as critical effect, an increased urinary excretion of microproteins. Studies carried out among industrial workers in the 1980s have derived a threshold of urinary Cd of 10 [micro]g/g creatinine for the development of tubular proteinuria with an increased urinary excretion of [[beta].sub.2]-microglobulin or retinol-binding protein (2,4,10,11). The validity of this threshold is again confirmed by the data shown in Table II, showing the relationship between retinol-binding protein and Cd in the urine of workers manufacturing cadmium-nickel batteries (unpublished data, Bernard et al). This threshold of 10 [micro]g/g creatinine for urinary Cd serves now the basis for the occupational exposure limit of 5 [micro]g/g creatinine currently in application in most industrialized countries. While the threshold of urinary Cd for the development of kidney damage has been estimated with some accuracy in industrial workers, thresholds of urinary Cd derived from population-based studies vary by almost one order of magnitude despite the use of the same indicators as in industrial workers (Table III). For instance, studies conducted in Belgium and Sweden have concluded that tubular dysfunction is likely to occur in the general population from thresholds of urinary Cd in the range of 1 to 2 [micro]g/g creatinine. By contrast, some studies on the general population of China and Japan have derived much higher thresholds in the range of 8 to 10 [micro]g/g creatinine, which actually agree well with that observed in industrial workers (Table III). Such inconsistencies might be linked to differences in sensitivity between adult workers and the general population. Methodological differences related to the use of benchmark dose rather than the lowest observed adverse effect level (LOAEL), the study of small-sized populations or analytical aspects such an insufficient adjustment for variations in diuresis, might account for part of the variation in these estimates. Another possibility that has received little attention is the confounding or distortion of dose-response relationships by parallel changes in the metabolism of Cd and in the renal function (related to ageing or diseases unrelated to Cd), generating secondary associations between protein and Cd in urine (39). Another possibility, also frequently overlooked, is a shift of the dose-response curve towards lower levels of Cd that necessarily occurs after removal from exposure, especially in subjects with renal damage (4,40). Diagnosis, treatment and prevention Diagnosis of chronic Cd poisoning basically relies on the screening of proximal tubular dysfunction and the assessment of the cumulative exposure to Cd using environmental or biological indicators. The earliest manifestation of Cd nephropathy consists in an increased urinary excretion of microproteins (tubular proteinuria). The most commonly microproteins are [[beta].sub.2]-microblubulin, retinol-binding protein and [alpha.sub.-1] microglobulin. These proteins are usually measured in untimed urine samples and the results are expressed per gram creatinine to adjust for variations in diuresis. The [[beta].sub.2]-microglobulin test presents the drawback that [[beta].sub.2]-microglobulin is unstable in urine samples with a pH above 5.6, which necessitates to collect a new urine sample in about 20-30 per cent of the cases. [Alpha.sub.1]microglobulin is very stable in urine but because of its larger size it is less specific of tubular damage and slightly less sensitive than the two other microproteins. Retinol-binding protein presents the advantage of being stable, specific and as sensitive as the [[beta].sub.2]-microglobulin. When tubular dysfunction is at an early stage, there is a possibility of some reversal at least when the Cd body burden is not too high (e.g. Cd in urine below 20 [micro]g/g creatinine). Otherwise, Cd-induced microproteinuria is irreversible and predictive of a faster decline of the GFR with ageing. There are no efficient treatments for chronic Cd poisoning. Even after cessation of exposure, renal dysfunction and pulmonary impairment may progress. The only possible intervention is removal from exposure. This means that in heath surveillance programmes, the emphasis must be placed on primary prevention in order to maintain the levels of Cd in the environment or in the food chain as low as possible (4). Acknowledgment The author declares that he has no financial competing interests. Received April 2, 2008 References (1.) Sethi PK, Khandelwal DJ. Cadmium exposure: health hazards of silver cottage industry in developing countries. Med Toxicol 2006; 2 : 14-5. (2.) Nordberg G, Nogawa K, Nordberg M, Friberg L. Cadmium. In: Handbook on toxicology of metals. Nordberg G, Fowler B, Nordberg M, Friberg, L editors New York: Academic Press, 2007. p. 65-78. (3.) Jarup L, Berglund M, Elinder CG, Nordberg G, Vahter M. Health effects of cadmium exposure--a review of the literature and a risk estimate. Scand J Work Environ Health 1998; 24 (Suppl 1) : 1-51. (4.) Bernard A. Renal dysfunction induced by cadmium: biomarkers of critical effects. Biometals 2004; 17:519-23. (5.) Sovet. Empoisonnement par une poudre servant a ecurer 3/4 argenterie: symptomes graves; gastro-enterite suraigue; accidents dyssenteriques; antidote; antiphlogistiques; ipecacuana; analyse chimique. Press Med Belge 1858; 10 : 69-70. (6.) Bulmer FMR, Rothwel HE, Frankish ER. Industrial cadmium poisoning. Can Public Hlth J 1938; 29 : 19-26. (7.) Nicaud P, Lafitte A, Gros A. Les troubles de l'intoxication chronique par le cadmium. Arch Mal Prof 1942; 4 : 192-202. (8.) Friberg L. Health hazards in the manufacture of alkaline accumulators with special reference to chronic cadmium poisoning; a clinical and experimental study. Acta Med Scand 1950; 240 : 1-124. (9.) Hagino N, Yoshioka Y. A study of the etiology of Itai-Itai disease. J Jpn Orthop Assoc 1961 ; 35 : 812-5. (10.) Bernard A, Lauwerys R. Effects of cadmium exposure in humans. In: Handbook of experimental pharmacology, E.C. Foulkes, editors Berlin: Springer-Verlag, 1986. p. 135-77. (11.) Bernard A, Roels H, Buchet JP, Cardenas A, Lauwerys R. Cadmium and health: the Belgian experience. IARC Sci Publ 1992; 118 : 15-33. (12.) Godt J, Scheidig F, Grosse-Siestrup C, Esche V, Brandenburg R Reich A, et al. The toxicity of cadmium and resulting hazards for human health. J Occup Med Toxicol 2006; 1 : 22. (13.) Bernard AM, Ouled Amor A, Lauwerys RR. The effects of low doses of cadmium-metallothionein on the renal uptake of beta 2-microglobulin in rats. Toxicol Appl Pharmacol 1987; 87 : 440-5 (14.) Nishijo M, Nakagawa H, Morikawa Y, Kuriwaki J, Katsuyuki M, Kido T, et al. Mortality in a cadmium polluted area in Japan. Biometals 2004; 17 : 535-8. (15.) Buchet JP, Lauwerys R, Roels H, Bernard A, Bruaux P, Claeys E et al. Renal effects of cadmium body burden of the general population. Lancet 1990; 336 : 699-702. (16.) Jarup L, Hellstrom L, Alfven T, Carlsson MD, Grubb A, Persson B, et al. Low level exposure to cadmium and early kidney damage: the OSCAR study. Occup Environ Med 2000; 57 : 668-72. (17.) Burbure C, Buchet JR Leroyer A, Catherine N, Haguenoer JM, Muni A, et al. Renal and neurological effects of cadmium, lead, mercury and arsenic in children: evidence of early effects and multiple interactions at environmental exposure levels. Environ Health Perspect 2006; 114 : 584-90. (18.) Akesson A, Lundh T, Vahter M, Bjellerup P, Lidfeldt J, Nerbrand C, et al. Tubular and glomerular kidney effects in Swedish women with low environmental cadmium exposure. Environ Health Perspect 2005; 113 : 1627-31. (19.) Bernard A. Biomarkers of metal toxicity in population studies: Research potential and interpretation issues. J Toxicol Environ Health 2008; 71 : 1259-65. (20.) Nordberg G, Jin T, Bernard A, Fierens S, Buchet JP, Ye T, et al. Low bone density and renal dysfunction following environmental cadmium exposure in China. Ambio 2002; 31 : 478-81. (21.) Qian HL, Jin TY, Kong QH, Wang HF, Zhu GY. Application of benchmark dose (BMD) in a bone-effect study on a general population environmentally exposed to cadmium. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2006; 24 : 23-6. (22.) Staessen JA, Roels HA, Emelianov D, Kuznetsova T, Thijs L, Vangronsveld J, et al. Environmental exposure to cadmium, forearm bone density, and risk of fractures: a prospective population study. Public Health and Environmental Exposure to Cadmium PheeCad) Study group. Lancet 1999; 353 : 1140-4. (23.) Jarup L, Alfven T. Low level cadmium exposure, renal and bone effects-the OSCAR study. Biometals 2004; 17 : 505-9. (24.) Akesson A, Bjellerup P, Lndh T, Lidefeldt J, Nerbrand C, Sansioe G, et al. Cadmium-induced effects on bone in population-based study of women. Environ Health Perspect 2006; 114 : 830-4. (25.) Wallin E, Rylander L, Jonssson BA, Lundh T, Isaksson A, Hagmar L. Exposure to CB- 153 and p,p'-DDE and bone mineral density and bone metabolism markers in middle-aged and elderly men and women. Osteoporos Int 2005; 16 : 2085-94. (26.) Waalkes ME Cadmium carcinogenesis. Mutat Res 2003; 533 : 107-20. (27.) Zeng X, Jin T, Jiang X, Kong Q, Ye T, Nordberg GE Effects on the prostate of environmental cadmium exposure-a cross-sectional population study in China. Biometals 2004; 17 : 559-65 (28.) Nawrot T, Plusquin M, Hogervorst J, Roels HA, Celis H, Thijs L, et al. Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncol 2006; 7: 119-26. (29.) Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, Guallar E. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect 2008; 116 : 51-6. (30.) Ishizaki M, Kido T, Honda R, Tsuritani I, Yamada Y, Nakagawa H, et al. Dose-response relationship between urinary cadmium and beta2-microglobulin in a Japanese environmentally cadmium exposed population. Toxicology 1989; 58 : 121-31 (31.) Ikeda M, Ezaki T, Tsukahara T, Moriguchi J, Furuki K, Fukui Y, et al. Threshold levels of urinary cadmium in relation to increases in urinary beta2-microglobulin among general Japanese populations. Toxicol Lett 2003; 137 : 135-41. (32.) Ezaki T, Tsukabara T, Moriguchi J, Furuki K, Fukui Y, Ukai H, et al. No clear-cut evidence for cadmium-induced renal tubular dysfunction among over 10,000 women in the Japanese general population: a nationwide large-scale survey. Int Arch Occup Environ Health 2003; 76 : 186-96. (33.) Ikeda M, Ezaki T, Moriguchi J, Fukui Y, Ukai H, Okamoto S, et al. The threshold cadmium level that causes a substantial increase in beta2-microglobulin in urine of general populations. Tohoku J Exp Med 2005; 205 : 247-61. (34.) Uno T, Kobayashi E, Suwazono Y, Okubo Y, Miura K, Sakata K, et al. Health effects of cadmium exposure in the general environment in Japan with special reference to the lower limit of the benchmark dose as the threshold level of urinary cadmium. Scand J Work Environ Health 2005; 31 : 307-15. (35.) Kobayashi E, Suwazono Y, Uetani M, Inaba T, Oishi M, Kido T, et al. Estimation of benchmark dose for renal dysfunction in a cadmium non-polluted area in Japan. J Appl Toxicol 2006; 26 : 351-5. (36.) Gamo M, Ono K, Nakanishi J. Meta-analysis for deriving age-and gender-specific dose-response relationships between urinary cadmium concentration and beta2-microglobulinuria under environmental exposure. Environ Res 2006; 101 : 104-12. (37.) Shimizu A, Kobayashi E, Suwazono Y, Uetani M, Oishi M, Inaba T, et al. Estimation of benchmark doses for urinary cadmium based on beta2-microglobulin excretion in cadmium-polluted regions of the Kakehashi River basin, Japan. Int J Environ Health Res 2006; 16 : 329-37. (38.) Kobayashi E, Suwazono Y, Uetani M, Inaba T, Oishi M, Kido T, et al. Estimation of benchmark dose as the threshold levels of urinary cadmium, based on excretion of total protein, beta2-microglobulin, and N-acetyl-beta-D-glucosaminidase in cadmium nonpolluted regions in Japan. Environ Res 2006; 101 : 401-6. (39.) Moriguchi J, Ezaki T, Tsukahara T, Fukui Y, Ukai H, Okamoto S, et al. Effects of aging on cadmium and tubular dysfunction markers in urine from adult women in non-polluted areas. Int Arch Occup. Environ Health 2005; 78 : 446-51. (40.) Bernard AM, Lauwerys RR. Dose-response relations between urinary cadmium and tubular proteinuria in adult workers. Am J Ind Med 1997; 31 : 116-8. Reprint requests: Dr A. Bernard, Unit of Toxicology, Faculty of Medicine, Catholic University of Louvain Dr. Avenue E. Mounier 53.02, B-1200, Brussels Belgium e-mail: bernard@toxi.ucl.ac.be A. Bernard Department of Public Health, Catholic University of Louvain, Belgium Table I. Interpretation of elevated values of urinary [[beta].sub.2]-
microglobulin ([[beta].sub.2],-M) and retinol-binding protein (RBP)
induced by occupational or environmental exposure to Cd
[[beta].sub.2],-M or RBP in Significance
urine ([micro]g/g
creatinine)
<300 Normal value
300- 1,000 Incipient Cd tubulopathy(possibility of
some reversal after removal of exposure
if urinary Cd is not too high i.e. below
20 [micro]g/g cr)
1,000-10,000 Irreversible tubular proteinuria that may
accelerate the decline of glomerular
filtration rate with age. At this stage
glomerular filtration rate is normal or
slightly impaired.
> 10,000 Overt Cd nephropahy usually associated
with a decreased glomerular filtration
rate
Modified from Ref. 4
Table II. Risks of increased urinary excretion of retinol-binding
protein (RBP-U) according to the urinary concentration of Cd
(Cd-U) in workers manufacturing nickel-cadmium batteries
Retinol-binding
protein in
urine ([micro]g
Cd-U ([micro] /g cr)
Cadmium in urine Number of /g cr median
([micro]g/g cr, range) workers (IQR) median (IQR)
0-1 112 0.55 (0.35-0.71) 95.1 (73.4-128)
> 1-2 92 1.40 (1.13-1.58) 96.8 (67.4-134)
> 2-5 130 3.35 (2.59-4.03) 98.0 (78.0-156)
> 5-10 67 6.97 (5.79-8.43) 120 (98.4-158)
10 50 14.0 (11.1-17.8) 178 (107-329) *
Retinol-binding protein in urine
([micro]g/g cr)
Old ration for
Cadmium in urine RBP-U >300
([micro]g/g cr, range) N > 300 (%) (95% CI) P-value
0-1 4 (3.57) 1.00 (1.00-1.00) --
> 1-2 3 (3.26) 0.91 (0.2-4.18) 0.90
> 2-5 3 (2.31) 0.65 (0.14-2.96) 0.58
> 5-10 2 (2.99) 0.83 (0.15-4.60) 0.83
10 15 (30.0) (+) 11.6 ( 3.60-37.2) < 0.0001
Statistical tests were performed using as reference the group of
workers with a Cd-U value lower than 1 [micro]g/g cr.
P<0.05 by the Dunett's multiple comparison test; * P<0.05 by the
[Chi.sup.2] test. The P values given in the Table indicate the
level of statistical significance of the odds for having a
RBP-U higher than 300 [micro]g/g cr.
Cd-U, cadmium concentration in urine; RBP-U, retinol-binding protein
concentration in urine; IQR, interquartile range; cr, creatinine
Table III. Estimates of the critical concentrations of Cd in urine
associated with tubular proteinuria in environmentally exposed
populations
Authors Country Population
Ishizaki et al 1989 (30) Japan 3,178 persons, >50 yr in
Cd-polluted area 294
persons, >50 yr in a
Cd non polluted area
Buchet et al 1990 (15) Belgium 1.699 persons, 20-80 yr
in two Cd polluted areas
and in two control areas
Jarup et al 2000 (16) Sweden 1,021 subjects
environmentally or
occupationally exposed
Ikeda et al 2003 (31) Japan Literature survey: 12
publications, 32 groups
of men and 58 groups
of women
Ezaki et al 2003 (32) Japan >10,000 middle aged women
Ikeda et al 2005 (33) Japan Meta-analysis. 51
publications
Akesson et al 2005 (18) Sweden 820 women, age 53-64 yr,
in a non polluted area
Uno et at 2005 (34) Japan 410 men and 418 women,
aged 40-59 yr in
Cd non polluted area
Kobayashi et at 2006 (35) Japan 1,114 men, 1,664
women, >50 yr. in
non polluted areas
Gamo et at 2006 (36) Japan Populations
environmentally exposed
to Cd
Shimuzu et at 2006 (37) Japan 3,178 in a Cd polluted
area; 294 in a non
polluted area
Kobayashi et al 2006 (38) Japan 2,034 sujects, age>50
yr, in a non polluted
area
Authors Protein ([micro]g/g cr)
Ishizaki et al 1989 (30) [[beta].sub.2]-M Men, 3.8-4.0
Women, 3.8-4.1
Buchet et al 1990 (15) [[beta].sub.2]-M [[beta].sub.2]-
RBP M-M, 2.03
RBP, 1.83
Jarup et al 2000 (16) Protein HC 1
Ikeda et al 2003 (31) [[beta].sub.2]-M 10-12
Ezaki et al 2003 (32) [[beta].sub.2]-M Association with
Cd-U without
threshold
Ikeda et al 2005 (33) [[beta].sub.2]-M 8-9
Akesson et al 2005 (18) Protein HC 0.80
Uno et at 2005 (34) [[beta].sub.2]-M Men, 0.6-1.2
Women. 1.2-3.6
Kobayashi et at 2006 (35) [[beta].sub.2]-NI Men, 2.4
Women. 3.3
Gamo et at 2006 (36) [[beta].sub.2]-M 2-3
Shimuzu et at 2006 (37) [[beta].sub.2]-M Men, 2.9-4
Women, 1.5-3.6
Kobayashi et al 2006 (38) [[beta].sub.2]-M Men, 2.0
Authors Remarks
Ishizaki et al 1989 (30)
Buchet et al 1990 (15) Response rate of 10%.
Cut-off: [[beta].sub.2]-
M-M,189 [micro]g/
cr, RBP, 225 [micro]g/g cr
Jarup et al 2000 (16) Inflexion point
Ikeda et al 2003 (31) Inflexion point
Ezaki et al 2003 (32) Similar associations
with urinary Zn, Ca
and Mg
Ikeda et al 2005 (33) Cut-off, [[beta].sub.2]-
M >1,000
[micro]g/cr
Akesson et al 2005 (18) LOAEL
Uno et at 2005 (34) BMDL
Kobayashi et at 2006 (35) BMDL
Gamo et at 2006 (36) Cut-off, [[beta].sub.2]-
M,-M, 1,000
[micro]g/cr
Shimuzu et at 2006 (37) Cut-off, [[beta].sub.2]-
M, 1,000
[micro]g/cr, BMDL
Kobayashi et al 2006 (38) BMDL, non smokers
Cd-U, cadmiulm concentration in urine; [[beta].sub.2]=-M,
[[beta].sub.2]-microglobulim RBP, retinol-binding protein; LOAEL,
lowest observed adverse effect level; BMDL, benchmark dose lowest
level; cr, creatinine |
| Gale Copyright: | Copyright 2008 Gale, Cengage Learning. All rights reserved. |
Previous Article: Molecular toxicity of aluminium in relation to
neurodegeneration.
Next Article: Some forthcoming scientific events.
Next Article: Some forthcoming scientific events.